ALLSCHWIL, Switzerland, Aug. 27, 2002 (PRIMEZONE) -- Actelion (SWX:ATLN) announced today that company's bearer shares will list be listed on the SWX Main Market board as of Monday, September 9, 2002.
Actelion initially listed on the SWX New Market in April 2000. In less than three years, Actelion has grown from a startup company into a globally active biopharmaceutical company. Actelion's lead product, Tracleer(TM), is made available in key markets worldwide through the company's own subsidiaries.
Upon request by Actelion, the SWX Swiss Exchange waived the requirement for a listing prospectus. The trading symbol of Actelion, ATLN, will remain unchanged. The company will also continue to report full quarterly figures.
The last trading day for Actelion shares at the SWX New Market is Friday, September 6, 2002. A listing advertisement will be published on September 9, 2002 in selected Swiss newspapers. The ad will be also available through http://www.actelion.com.
Actelion Ltd.
Actelion Ltd. is a biopharmaceutical company, with its corporate headquarter in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(TM), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(TM) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union as well as Canada and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium the single layer of cells separating every blood vessel from the blood stream. Actelion focuses on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN).
Contact at Actelion Ltd., Gewerbestrasse 16, CH4123 Allschwil.